Schwab Kim, Smith Richard, Wager Eric, Kaur Sukhjit, Alvarez Lisa, Wagner Jordan, Leung Helen
Sharp Chula Vista Medical Center, Chula Vista, CA, United States of America.
Pfizer, Inc., New York, NY, United States of America.
Am J Emerg Med. 2021 Jun;44:315-322. doi: 10.1016/j.ajem.2020.04.019. Epub 2020 Apr 10.
Emergency departments (ED) in the United States see more than half a million atrial fibrillation visits a year, however guideline recommended anticoagulation is prescribed in <55% of eligible patients.
The purpose of this study was to measure guideline recommended anticoagulation prescribing in patients with nonvalvular atrial fibrillation (NVAF) presenting to the ED, with the goal of closing any treatment gap established.
We conducted an observational, prospective cohort study in consecutive patients presenting to the ED with a diagnosis of NVAF. CHA2DS2-VASc and HAS-BLED scores were calculated and used as predefined criteria to establish guideline-based oral anticoagulation compliance in comparing routine care (baseline cohort) versus a multidisciplinary team approach. Transition of Care (TOC) services and follow-up were also provided in the multidisciplinary cohort. The primary endpoint was to compare the proportion of patients on guideline based oral anticoagulant (OAC) therapy at admission and discharge between the groups.
In the Baseline Cohort (BC) (n = 99), 62.3% of patients with a moderate-high risk of stroke (CHA2DS2-VASc score ≥ 2) were discharged on guideline-based OAC therapy versus 87.8% in the Multidisciplinary Team Cohort (MTC) (n = 131), a 25.5% overall improvement for appropriate anticoagulation (p-value <.001, 95% CI (0.14-0.37)).
A multidisciplinary team approach with TOC services for the identification and early intervention of NVAF patients at risk of stroke in the ED can significantly improve the percentage of moderate to high-risk patients that are discharged home with guideline based OAC.
美国急诊科每年接待超过50万例心房颤动患者就诊,然而,符合条件的患者中,只有不到55%的患者按照指南建议接受了抗凝治疗。
本研究旨在衡量急诊科非瓣膜性心房颤动(NVAF)患者中指南推荐的抗凝治疗处方情况,以填补已发现的治疗差距。
我们对连续就诊于急诊科且诊断为NVAF的患者进行了一项观察性前瞻性队列研究。计算CHA2DS2-VASc和HAS-BLED评分,并将其作为预定义标准,用于比较常规护理(基线队列)与多学科团队方法之间基于指南的口服抗凝治疗依从性。多学科队列还提供了过渡护理(TOC)服务和随访。主要终点是比较两组患者入院时和出院时接受基于指南的口服抗凝剂(OAC)治疗的比例。
在基线队列(BC)(n = 99)中,中风中度至高度风险(CHA2DS2-VASc评分≥2)的患者中,62.3%在出院时接受了基于指南的OAC治疗,而多学科团队队列(MTC)(n = 131)中这一比例为87.8%,适当抗凝治疗总体改善了25.5%(p值<.001,95%CI(0.14-0.37))。
对于急诊科有中风风险的NVAF患者,采用多学科团队方法并提供TOC服务进行识别和早期干预,可以显著提高中度至高度风险患者出院时接受基于指南的OAC治疗的比例。